Biohaven Corp (BHVN): Market Cap to Revenue Ratio
Geopolitical tensions are limiting the export of neurological drugs, yet stable laboratory operations and capacity modernization are offsetting these risks. The historical P/S trend on the GURU.Markets terminal chart smooths out reporting noise, where the 1.40 value serves as the baseline valuation metric. The fundamentals of Biohaven Ltd. (BHVN) are based on the experience of the Nurtec creators and an innovative approach to treating severe CNS pathologies.
Analytical breakdowns for Biohaven Pharmaceutical (BHVN)
- current quotes and average value forecast:
- stock exchange capitalization data:
- business book valuation details:
- business debt structure and liquidity details:
Aggregate Debt to Capital Biohaven Ltd.|BHVN - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Biohaven Corp|BHVN - Company Total Debt|Debts to Net Assets Biohaven Pharmaceutical|BHVN - Company Long-Term Debts|Company Short-Term Debt Biohaven|Intermediate Coverage Ratio biohavenpharma.com
- earnings and valuation multiples information:
BHVN - Net Income|Expected Profit Biohaven Ltd.|BHVN - Price to Earnings Ratio|Price to Future Earnings Ratio Biohaven Ltd|BHVN - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Biohaven Pharmaceutical|BHVN - Operating profit EBITDA|Net earnings per one share for the last twelve months Biohaven|BHVN - Net earnings per share for the last 12 months|Quarterly EPS earnings growth biohavenpharma.com|BHVN - Earnings per share growth in current year|Expected earnings per share trend next year Biohaven Ltd.
- total revenue and sales volume data:
Summary company analytics:BHVN, biohavenpharma.com
A stable staff of neurobiologists and the absence of talent attrition at Biohaven Ltd. (BHVN) create a foundation for long-term sales growth, which directly capitalizes into the market value of the shares. By analyzing the current price-to-sales ratio, an investor assesses how many dollars of market value are attributed to one dollar of sales, making it possible to identify if the asset is overbought relative to its historical averages.
Competing companies
BIIB - Price to Sales|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|RGC: Market Cap to Revenue Ratio|AXSM: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Corp)|Xenon Pharmaceuticals (XENE) - Price-to-Revenue Ratio|VKTX (vikingtherapeutics.com) - Price-to-Revenue Ratio|Market Cap to Revenue SUPN|CPRX (Catalyst Pharma) - Market Cap to Sales Volume|P/S Multiple DNLI|Harmony Corp - Market Cap to Revenue Ratio|Amylyx Pharmaceuticals - Market Cap to Revenue|Price-to-Revenue Coefficient trevitherapeutics.com (TRVI)|Praxis Precision Medicines, Inc. - P/S Multiple|AVXL: Price-to-Revenue Ratio|CBLL: P/S Multiple|Prothena Corp - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue ALEC|Price-to-Revenue Ratio ANNX|Price-to-Revenue Ratio Omeros Corporation (OMER)|Neurogene Inc - Market Cap to Revenue Ratio|Price-to-Revenue Ratio AC Immune Corp ACIU|VYGR: Market Cap to Revenue Ratio|Neumora Therapeutics - P/S Multiple|Price to Sales scilexholding.com|TVGN (Tevogen Bio) - Market Cap to Revenue|Alpha Cognition Inc. (ACOG) - P/S Multiple|Price-to-Revenue Ratio Cognition Therapeutics, Inc.|IKT: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Cassava Sciences, Inc. (SAVA)|ASRT - Price to Sales|P/S Multiple COYA (Coya Therapeutics)|VistaGen Therapeutics, Inc. - Price-to-Revenue Ratio|Ovid Rx - P/S Multiple|Price-to-Revenue Coefficient Acumen Pharmaceuticals, Inc ABOS|CervoMed Inc. (CRVO) - Price-to-Revenue Ratio|Price to Sales Alterity Therapeutics Limited (ATHE)|CLNN (Clene Inc) - P/S Multiple|PEPG: Market Capitalization-to-Revenue Ratio|P/S Multiple JUNS|P/S Multiple Relmada Corp (RLMD)|Annovis Bio, Inc. - Market Cap to Revenue|Grace Therapeutics Inc - Price-to-Revenue Ratio|Firefly Neuroscience - P/S Multiple|Price to Sales Klotho Neurosciences Inc|neurosense-tx.com (NRSN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio RVPH|Market Cap to Revenue MTVA|NRXS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Helius Medical (HSDT)|Price-to-Revenue Ratio PASG (passagebio.com)|Neuphoria Therapeutics - Market Cap to Revenue|Market Cap to Sales Volume NERV (Minerva)|Athira Pharma, Inc. - P/S Multiple|ADXN (addextherapeutics.com) - Market Cap to Revenue Ratio|ALZN (alzamend.com) - Market Cap to Revenue|CYCN - Price-to-Revenue Coefficient|PTIX (Protagenic Therapeutics Inc.) - P/S Multiple|Price-to-Revenue Ratio KTTA|P/S Multiple CRGT|ATXI (avenuetx.com) - Market Capitalization-to-Revenue Ratio|BrainStorm Cell Therapeutics - Market Cap to Revenue|Cara Therapeutics Inc. - Price-to-Revenue Ratio|CHRO - Price-to-Revenue Ratio|ELYM (Eliem Therapeutics) - Market Cap to Revenue Ratio|intracellulartherapies.com (ITCI) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio LBPH|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|Price to Sales NKGen Biotech Inc NKGN|Market Cap to Revenue NRBO (NeuroBo)|P/S Multiple Sage Therapeutics Inc (SAGE)|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|Market Capitalization-to-Revenue Ratio TRVN|VIGL - Price-to-Revenue Ratio|Price to Sales anewmeds.com|CERE: P/S Multiple
